Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma

Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma

Introduction Primary Mediastinal Large B Cell Lymphoma (PMLBCL) is a rare but aggressive B-cell lymphoma. This study compares the outcomes and toxicities of DA-EPOCH-R (Dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin in combination with rituximab) and RCHOP-21 (...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammad Ma'koseh, Abeer Yaseen, Nebras Abu Abed, Omar Shahin, Alaa Abufara, Khalid Halahleh, Mohammad Al-Rwashdeh, Zaid Abdel Rahman, Ro’a Muqbel, Heba Farfoura, Akram Al-Ibraheem, Kamal Al-rabi, Hikmat Abdel-Razeq
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Hematology
Subjects:
Mediastinal large B-cell lymphoma
DA-EPOCH-R
RCHOP
Radiotherapy
aa-IPI
relapse
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2025.2515337
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2025.2515337

Similar Items